Navigation Links
New drug agent knocks out multiple enzymes in cancer pathway
Date:3/25/2009

A team of 24 researchers from the U.S., Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.

The study appears this week in the Journal of the American Chemical Society.

The new agent belongs to a class of drugs called bisphosphonates. These compounds were originally developed to treat osteoporosis and other bone diseases, but were recently found to also have potent anti-cancer and immune boosting properties.

Drug developers have tried for years to design drugs to inhibit cell survival pathways in tumor cells, focusing on a protein called Ras since nearly a third of all human cancers involve a mutation in the Ras gene that causes cell signaling to go awry. These efforts have met with limited success.

Bisphosphonates act on other enzymes, called FPPS and GGPPS, which are upstream of Ras in the cell survival pathway. Inhibiting these enzymes appears to be a more effective strategy for killing cancer cells.

When used in combination with hormone therapy in a recent clinical trial, the bisphosphonate drug zoledronate significantly reduced the recurrence of breast cancer in premenopausal women with estrogen-receptor-positive breast cancer. Similar results were reported previously for hormone-refractory prostate cancer.

But zoledronate quickly binds to bone, reducing its efficacy in other tissues.

"We're trying to develop bisphosphonates that will be very active but won't bind to the bone, because if they bind to the bone they're not going to go to breast, lung or other tissues," said University of Illinois chemistry professor Eric Oldfield, who led the new study.

Oldfield's team also wanted to design a compound that would inhibit multiple enzymes in the tumor cell survival pathway, rather than just one, an approach analogous
'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert  

3

GOOD

Page: 1 2

Related biology news :

1. Structure of enzyme against chemical warfare agents determined
2. Chemopreventive agents in black raspberries identified
3. MIT nanotubes sniff out cancer agents in living cells
4. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
5. Certain anticancer agents could be harmful to patients with heart disease
6. UF researchers develop improved gene therapy agent
7. New insights into the diversity of Creutzfeldt-Jakob disease agents
8. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
9. Contrast agent trials in swine
10. Agent that triggers immune response in plants is uncovered
11. Primate behavior explained by computer agents
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New drug agent knocks out multiple enzymes in cancer pathway
(Date:5/21/2013)... Mass. , May 21, 2013 Royal ... CX50 xMATRIX, the world,s first portable ultrasound with Philips, ... Echo (ICE) capability. The CX50 xMATRIX with available Live ... Paris at the EuroPCR, official meeting ... May 21-24. Since its launch in 2012, ...
(Date:5/20/2013)... of Minnesota Medical School researchers from the Masonic Cancer ... Brain Tumor Program, have developed a new mouse model ... them to discover new genes and gene pathways driving ... this week in the journal Nature Genetics . ... the lab of David Largaespada, Ph.D., professor in the ...
(Date:5/20/2013)... a compound abundant in the Mediterranean diet takes away ... altering a very specific step in gene regulation, this ... die as scheduled. , One way that cancer cells ... them to die on a regular cycle that is ... by Ohio State University researchers, found that a compound ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2U of M researchers develop model for better testing, targeting of MPNST 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3
... pales in comparison with the latest creation of Rice ... of the University of Wisconsin-Madison and Donald Argus of ... put the finishing touches on a 20-year labor of ... the interlocking tectonic plates that account for about 97 ...
... Pediatric researchers analyzing DNA variations in type 1 diabetes ... of genes. Some genes have opposing effects, raising the ... In other cases, a gene variant may act in ... Both type 1 diabetes (T1D) and inflammatory bowel ...
... Energy (DOE) Joint Genome Institute (JGI) has two entries ... Applied Ergonomics Conference held March 22-25, 2010 in San ... category, the DOE JGI,s entry is "Empowering Employees in ... JGI program that help promote awareness of ergonomics and ...
Cached Biology News:Tectonics: Precision is hallmark of 20-year study 2Tectonics: Precision is hallmark of 20-year study 3Genes may exert opposite effects in diabetes and inflammatory bowel disease 2DOE JGI vying for 2010 Ergo Cup 2
(Date:5/21/2013)... (PRWEB) May 21, 2013 Custom ... to reporting eLearning solution using Tin Can API ... dashboard tool. CLD is a leading developer of ... medical device companies worldwide. , Tin Can ... that helps learners and trainers more accurately measure ...
(Date:5/21/2013)... , May 21, 2013 The ... and Transplant Association) is the biggest congress in ... therapy. Nearly 10,000 participants are in Istanbul ... latest research findings. New pioneering studies have been presented: ... FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" ...
(Date:5/21/2013)... May 21, 2013 According to ... ( http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the ... and is expected to grow at a CAGR of ... value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... poised to take their business to the $1 million annual ... prize packages, and business mentoring when the Make Mine ... here May 21. , ,The all-day event, which will take ... to women-owned businesses, including those in the technology and life ...
... Hanlon sees a lot of parallels between riding a motorcycle and ... has skinned his knees attempting to do both. , ,Hanlon will ... during the Wisconsin Alumni Research Foundation's Gilson Series ... managing an emerging-growth company. , ,While he figures to be speaking ...
... capital in more deals in 2006, but the improvement was ... Ernst & Young, LLP and Dow Jones VentureOne ... 2006, including a $12 .5 million round by NimbleGen ... a total of $58.47 million. The total, up from the ...
Cached Biology Technology:Women's entrepreneurial event set for May 21 2Motorcycling entrepreneur to speak in Madison on success, failure, capital 2Motorcycling entrepreneur to speak in Madison on success, failure, capital 3Wisconsin fares slightly better in venture capital chase 2Wisconsin fares slightly better in venture capital chase 3
...
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
...
Biology Products: